secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2022-07-21T23:59:59+00:00
Accession:  0001077183-22-000124
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics appoints Chris Smith as CEO effective Aug 15, 2022; Tetrault resumes Chair
--------------------------------------------------------------------------------

- Chris Smith, former CEO of Ortho Clinical Diagnostics, appointed CEO effective August 15, 2022.
- Base salary $1M/year, target annual bonus 100% of salary, inducement awards ~$8.5M (RSUs and options).
- Interim CEO Lynn Tetrault steps down and resumes role as independent Chair of the Board.
- Smith led Ortho Clinical through its IPO ($1.45B) and Quidel merger; previously CEO of Cochlear (2015-2018).
- Relocation benefits up to $400K; severance: 1x salary+bonus (non-CIC) or 3x salary+bonus (CIC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/0001077183-22-000124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/neo-20220720.htm
  HTML page:      https://secwatch.observer/filing/0001077183-22-000124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer